Val Gebski

35.2k total citations · 12 hit papers
470 papers, 20.5k citations indexed

About

Val Gebski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Val Gebski has authored 470 papers receiving a total of 20.5k indexed citations (citations by other indexed papers that have themselves been cited), including 186 papers in Oncology, 118 papers in Pulmonary and Respiratory Medicine and 105 papers in Surgery. Recurrent topics in Val Gebski's work include Ovarian cancer diagnosis and treatment (52 papers), Endometrial and Cervical Cancer Treatments (48 papers) and Breast Cancer Treatment Studies (43 papers). Val Gebski is often cited by papers focused on Ovarian cancer diagnosis and treatment (52 papers), Endometrial and Cervical Cancer Treatments (48 papers) and Breast Cancer Treatment Studies (43 papers). Val Gebski collaborates with scholars based in Australia, United States and New Zealand. Val Gebski's co-authors include B. Mark Smithers, Bryan Burmeister, John Zalcberg, John Simes, Anthony Keech, R. J. Simes, Chee Khoon Lee, Michael Veness, Sarah J. Lord and James Chih‐Hsin Yang and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Val Gebski

449 papers receiving 19.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

2011 1.2k citations Katrin Marie Sjoquist, B. Mark Smithers et al. profile →
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer

2018 1.1k citations Kristy Robledo, Val Gebski et al. profile →
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis

2007 912 citations Val Gebski, B. Mark Smithers et al. profile →
Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer

2015 700 citations Andrew R. L. Stevenson, Val Gebski et al. profile →
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial

2005 696 citations B. Mark Smithers, Val Gebski et al. profile →
Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis

2016 582 citations Chee Khoon Lee, Sarah J. Lord et al. profile →
Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer

1987 419 citations Val Gebski, G Gill et al. profile →
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

2010 410 citations Éric Pujade-Lauraine, Uwe Wagner et al. Journal of Clinical Oncology profile →
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma

2017 405 citations Chee Khoon Lee, Sarah J. Lord et al. profile →
Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

2013 383 citations Chee Khoon Lee, Chris Brown et al. profile →
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

2012 369 citations Val Gebski et al. profile →
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial

2020 213 citations Gary Wittert, Karen Bracken et al. profile →

Peers

Countries citing papers authored by Val Gebski

Since Specialization

Citations

This map shows the geographic impact of Val Gebski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Val Gebski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Val Gebski more than expected).

Fields of papers citing papers by Val Gebski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Val Gebski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Val Gebski. The network helps show where Val Gebski may publish in the future.

Co-authorship network of co-authors of Val Gebski

This figure shows the co-authorship network connecting the top 25 collaborators of Val Gebski. A scholar is included among the top collaborators of Val Gebski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Val Gebski. Val Gebski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long Term Functional Outcomes After Transabdominal Versus Transanal Total Mesorectal Excision: A Matched Comparative Study 2025 ·ANZ Journal of Surgery ·(unknown), Steven Lau, (unknown), (unknown), Tim Eglinton, (unknown), Alexander G. Heriot, Satish K. Warrier, Glenn Guest, Arend E. H. Merrie, Stephen Bell, Val Gebski, Andrew R. L. Stevenson, David A. Clark	0
2	LBA58 A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG 2024 ·Annals of Oncology ·Trevor Leong, B. Mark Smithers, (unknown), Karin Haustermans, (unknown), Val Gebski, P. R. O’Connell, John Zalcberg, Alex Boussioutas, Michael Findlay, David J. Willis, Angela Moore, Florian Lordick, Claire O’Callaghan, (unknown), Gail Darling, A. H. Strickland, (unknown), Laurent Mineur, John Simes	1
3	Groin Surveillance by Serial Ultrasonography Rather Than Sentinel Node Biopsy or Inguinofemoral Lymphadenectomy for Patients with Vulvar Cancer: A Pilot Study 2023 ·Cancers ·Neville F. Hacker, Ellen Barlow, (unknown), Stephen Morrell, Val Gebski, Andreas Obermair	4
4	Neuropsychiatric correlates of olfactory identification and traumatic brain injury in a sample of impulsive violent offenders 2023 ·Frontiers in Psychology ·(unknown), Tony Butler, (unknown), Kay Wilhelm, Philip B. Mitchell, (unknown), David A. Greenberg, (unknown), Val Gebski, Peter W. Schofield	1
5	586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial 2023 ·Annals of Oncology ·Daphne Day, (unknown), Val Gebski, John Simes, Theresa Hayes, (unknown), A. H. Strickland, Karen Briscoe, Suresh Varma, (unknown), Christopher Jackson, Lisa G. Horvath, Timothy Price, Niall C. Tebbutt, (unknown), Connie I. Diakos, (unknown), Han Chong Toh, Frederick S. Jones, Eva Segelov	1
6	Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer 2023 ·British Journal of Cancer ·(unknown), (unknown), (unknown), Michael Friedländer, Val Gebski, Alain Lortholary, Florence Joly, Annette Hasenburg, Mansoor Raza Mirza, Ursula Denison, Sabrina Chiara Cecere, Annamaria Ferrero, Éric Pujade-Lauraine, Chee Khoon Lee	4
7	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis 2022 ·European Journal of Cancer ·(unknown), (unknown), (unknown), Val Gebski, Sarah J. Lord, Michael Friedländer, Chee Khoon Lee	3
8	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy 2021 ·European Journal of Cancer ·(unknown), Michael Friedländer, Sarah J. Lord, Rebecca Asher, Manuel Rodrigues, Jonathan A. Ledermann, Ursula A. Matulonis, Amit M. Oza, Ilan Bruchim, Tomasz Huzarski, Charlie Gourley, Philipp Harter, Ignace Vergote, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tsveta Milenkova, Éric Pujade-Lauraine, Val Gebski, Chee Khoon Lee	9
9	Combination chemotherapy with NAB^®‐paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP‐CAPABIL Pilot Study) 2021 ·Asia-Pacific Journal of Clinical Oncology ·Rachel Woodford, Daniel Brungs, (unknown), Peter Grimison, Katrin Marie Sjoquist, Therese M. Becker, Samuel Robinson, Val Gebski, Kate Wilson, Lorraine A. Chantrill, Morteza Aghmesheh	8
10	Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring 2021 ·BMC Cancer ·(unknown), Doan Trang Nguyen, T. B. Moodie, Ricky O’Brien, (unknown), Andrew J. Hickey, (unknown), P.R. Poulsen, (unknown), Britta Weber, E. Worm, David Pryor, Julie Chu, Nicholas Hardcastle, Jeremy Booth, Val Gebski, Wei Wang, Paul Keall	5
11	A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trial 2019 ·Clinical Trials ·Karen Bracken, Anthony Keech, Wendy Hague, Carolyn A Allan, Ann J. Conway, Mark Daniel, Val Gebski, Mathis Grossmann, David J. Handelsman, Warrick J. Inder, Alicia J. Jenkins, Robert I. McLachlan, Kristy Robledo, Bronwyn Stuckey, Bu B. Yeap, Gary Wittert	1
12	Long‐term outcomes in 1121 Australian prostate cancer patients treated with definitive radiotherapy 2018 ·Journal of Medical Imaging and Radiation Oncology ·(unknown), Andrew Kneebone, Val Gebski, (unknown), Viet Do, Amy Hayden, (unknown), Mark Sidhom, Sandra Turner	2
13	Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer 2017 ·JMIR Research Protocols ·Pradeep S. Virdee, Joanna Moschandreas, Val Gebski, Sharon Love, (unknown), Harpreet Wasan, Guy van Hazel, Peter Gibbs, Ricky A. Sharma	12
14	Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial 2017 ·PLoS Medicine ·Karen Canfell, Michael Caruana, Val Gebski, (unknown), Stella Heley, Julia Brotherton, Dorota M. Gertig, (unknown), Annabelle Farnsworth, Jeffrey Tan, C. David Wrede, Philip E. Castle, Marion Saville	62
15	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study 2016 ·Clinical Cancer Research ·Peter Fox, Rosemary L. Balleine, (unknown), Bo Gao, Bavanthi Balakrishnar, Alexander M. Menzies, (unknown), Sayed Ali, Val Gebski, Pamela Provan, Sally Coulter, Christopher Liddle, Rina Hui, Richard Kefford, Jodi Lynch, Mark Wong, Nicholas Wilcken, Howard Gurney	64
16	Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse breakdown → 2010 ·Journal of Clinical Oncology ·Éric Pujade-Lauraine, Uwe Wagner, (unknown), Val Gebski, M. Heywood, P. Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero, Jalid Sehouli, Alain Lortholary, Gunnar B. Kristensen, Christian Jackisch, Florence Joly, Chris Brown, Nathalie Le Fur, Andreas du Bois	410
17	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study 2010 ·Journal of Clinical Oncology ·Niall C. Tebbutt, Kate Wilson, Val Gebski, Michelle M. Cummins, Diana Zannino, Guy A. Van Hazel, Bridget A. Robinson, A. Broad, Vinod Ganju, Stephen P. Ackland, Garry Forgeson, David Cunningham, Mark Saunders, Martin R. Stockler, (unknown), John Zalcberg, R. J. Simes, Timothy Price	315
18	Metastatic cutaneous squamous cell carcinoma of the head and neck 2009 ·Cancer ·(unknown), Gary J. Morgan, Carsten E. Palme, (unknown), Jennifer Shannon, (unknown), Val Gebski, Michael Veness	101
19	Basal cell carcinoma of the nose: An Australian and New Zealand Radiation Oncology patterns‐of‐practice study 2008 ·Journal of Medical Imaging and Radiation Oncology ·MJ Veness, (unknown), K. W. Tiver, Val Gebski	8
20	Health-related quality of life (HRQL) before and 1 month after axillary surgery in a randomized trial of sentinel node (SN) biopsy versus axillary clearance (AC): the SNAC Trial. 2004 ·Breast Cancer Research and Treatment ·Anna K. Nowak, Carolyn Hargreaves, G Gill, Neil Wetzig, Owen Ung, Ian Campbell, James Kollias, Lisa J. Young, (unknown), Val Gebski, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact